Success Metrics

Clinical Success Rate
73.3%

Based on 22 completed trials

Completion Rate
73%(22/30)
Active Trials
2(5%)
Results Posted
68%(15 trials)
Terminated
8(21%)

Phase Distribution

Ph phase_2
22
58%
Ph not_applicable
1
3%
Ph early_phase_1
1
3%
Ph phase_1
7
18%
Ph phase_3
4
11%
Ph phase_4
1
3%

Phase Distribution

8

Early Stage

22

Mid Stage

5

Late Stage

Phase Distribution36 total trials
Early Phase 1First-in-human
1(2.8%)
Phase 1Safety & dosage
7(19.4%)
Phase 2Efficacy & side effects
22(61.1%)
Phase 3Large-scale testing
4(11.1%)
Phase 4Post-market surveillance
1(2.8%)
N/ANon-phased studies
1(2.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

22 of 33 finished

Non-Completion Rate

33.3%

11 ended early

Currently Active

2

trials recruiting

Total Trials

38

all time

Status Distribution
Active(2)
Completed(22)
Terminated(11)
Other(3)

Detailed Status

Completed22
Terminated8
unknown3
Withdrawn3
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
38
Active
2
Success Rate
73.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.8%)
Phase 17 (19.4%)
Phase 222 (61.1%)
Phase 34 (11.1%)
Phase 41 (2.8%)
N/A1 (2.8%)

Trials by Status

unknown38%
withdrawn38%
completed2258%
terminated821%
active_not_recruiting13%
recruiting13%

Recent Activity

Clinical Trials (38)

Showing 20 of 38 trialsScroll for more
NCT06636734Phase 2

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Recruiting
NCT02964884Phase 2

Interventions for Reading Disabilities in NF1

Active Not Recruiting
NCT03504501Phase 2

Synaptic Plasticity and Cognitive Function in RASopathies

Terminated
NCT03510884Phase 3

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Completed
NCT00302952Phase 2

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Terminated
NCT02998151Early Phase 1

Neurophysiological and Acute Pharmacological Studies in FXS Patients

Completed
NCT00700921Phase 2

Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT03510715Phase 3

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Completed
NCT04297033Phase 2

Lovastatin for Treatment of Brain Arteriovenous Malformations

Unknown
NCT02642653Phase 4

Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome

Completed
NCT02563860Phase 2

Pharmacological Treatment of Rett Syndrome With Statins

Completed
NCT01478828Not Applicable

Pre-Prostatectomy Lovastatin on Prostate Cancer

Terminated
NCT00584012Phase 1

A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer

Terminated
NCT00853580Phase 2

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

Completed
NCT00583102Phase 1

Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML

Terminated
NCT00585052Phase 2

A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer

Terminated
NCT03242499Phase 2

Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease

Unknown
NCT00285857Phase 2

Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention

Terminated
NCT02603770Phase 1

Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers

Completed
NCT00352599Phase 1

Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
38